The closing months of the calendar year represent a critical nexus for the oncology community, particularly for those dedicated to the study and treatment of metastatic breast cancer (MBC). For METAvivor Research and Support, a leading non-profit organization dedicated to funding research for Stage IV breast cancer, the period between Thanksgiving and the New Year is defined by a rigorous schedule of scientific exchange, strategic planning, and the adjudication of multi-million dollar research grants.
Led by President Kelly Shanahan, M.D., the organization recently concluded its high-profile participation at the San Antonio Breast Cancer Symposium (SABCS), the world’s premier conference for breast cancer researchers and clinicians. This year’s activities underscore a pivotal shift in the landscape of oncology: the transition of patient advocates from passive recipients of care to active, essential colleagues in the scientific process. As the organization prepares to announce its 2024 grant recipients, the intersection of patient expertise and clinical innovation has never been more visible.
Main Facts: A Dual Focus on Advocacy and Innovation
The core of METAvivor’s mission is the belief that metastatic breast cancer deserves a dedicated share of research funding—a share that historically has been disproportionately low compared to early-stage research. In the recent year-end cycle, the organization’s efforts have focused on three primary pillars: scientific investment, programmatic expansion, and global advocacy.
The 2023-2024 Grant Cycle
One of the most significant developments is the progression of METAvivor’s annual grant cycle. The organization received nearly 200 Letters of Intent (LOIs) from researchers across the globe. Following a rigorous vetting process by the Scientific Advisory Board, 65 investigators were invited to submit full applications. Ultimately, 62 comprehensive proposals were received and are currently under final review. These applications are categorized into three critical streams:
- Translational Research (36 applications): Focusing on moving laboratory discoveries into clinical applications.
- Early Career Awards (16 applications): Supporting the next generation of MBC specialists.
- Quality of Life (10 applications): Investigating methods to improve the daily lived experience of those with Stage IV disease.
Strategic Presence at SABCS
METAvivor maintained a robust presence at SABCS in San Antonio, Texas. The delegation included Executive Director Crystal Moore and Board President Dr. Kelly Shanahan, alongside board members Janice Cowden, Amy Beumer, Nathaniel Robinson, and Sharon Anderson. The team engaged in 11 formal sponsorship meetings and numerous informal sessions designed to secure the financial future of the organization’s various support programs.
Programmatic Evolution: R.I.S.E. and Peer Support
The organization is also moving forward with "R.I.S.E." (Reach. Inform. Support. Empower), an initiative designed to reinvent the "Sea to Sea for MBC" program. This program aims to bridge the gap in care for under-resourced populations, ensuring that the benefits of modern research and support reach all demographics regardless of socioeconomic status. Furthermore, the METAvivor Peer-to-Peer support model is gaining international traction, with new interest from oncologists in North Africa.
Chronology: From Thanksgiving to the New Year
The timeline of METAvivor’s year-end activities reflects the "frantic" yet productive nature of the advocacy world.
Late November: The Grant Review Kickoff
Immediately following the Thanksgiving holiday, the METAvivor Board of Directors and the Scientific Advisory Board (SAB) began the arduous task of reviewing full grant applications. This period is crucial, as the number of grants awarded is directly tethered to the total funds raised throughout the fiscal year. Unlike many other organizations, METAvivor directs 100% of its donations toward research, making the year-end fundraising push a literal lifeline for future scientific breakthroughs.
Early December: The San Antonio Breast Cancer Symposium (SABCS)
The first full week of December was dominated by SABCS. For the METAvivor team, this involved a grueling schedule of scientific sessions, panel discussions, and networking.
- Day 1-2: Focus on plenary sessions and the introduction of new clinical trial data. Dr. Shanahan and the team began meetings with potential corporate and private sponsors.
- Day 3-4: Board members Janice Cowden and Amy Beumer participated in panel discussions. Their role was to provide the "expert patient" perspective, ensuring that the human element of the disease remained central to the scientific discourse.
- Day 5: Closing sessions and international outreach. Dr. Shanahan met with oncologists from Morocco to discuss the implementation of peer-to-peer training in developing advocacy groups abroad.
Late December to Early January: Implementation and Announcements
Following the symposium, the organization entered a phase of follow-up and administrative finalization. This includes the preparation of the R.I.S.E. survey, scheduled for release in early January, and the finalization of grant award letters. The official announcement of the 2024 grant recipients is slated for the first week of January, marking the start of a new year of funded research.
Supporting Data: Quantifying the Impact
The scale of METAvivor’s operations can be seen in the metrics of their recent activity. The transition from 200 LOIs to 62 full applications represents a highly competitive selection process, ensuring that only the most promising and impactful research receives funding.
| Grant Category | Number of Applications | Primary Goal |
|---|---|---|
| Translational | 36 | Bridging the gap between bench science and clinical trials. |
| Early Career | 16 | Retention of talent in the metastatic breast cancer field. |
| Quality of Life | 10 | Managing side effects, mental health, and palliative care. |
| Advisor’s Award | 1 | Recognition of high-level scientific contribution. |
The physical and logistical demands of SABCS also provide insight into the intensity of the work. Dr. Shanahan noted an average of 10,000 steps per day during the symposium, highlighting the sheer scale of the event which hosts thousands of delegates. This level of engagement is necessary to maintain METAvivor’s position at the forefront of the MBC conversation.
Official Responses: The Evolving Role of the Advocate
One of the most poignant moments of the recent symposium came from Dr. Dennis Slamon, the renowned oncologist instrumental in the development of trastuzumab (Herceptin). In a plenary session, Dr. Slamon issued a statement that has since become a rallying cry for METAvivor:
"Advocates are not just fundraisers and cheerleaders for research; we are colleagues whose inclusion in the design of clinical trials makes the trials better and innovation faster."
This sentiment was echoed by Dr. Shanahan, who emphasized that patient advocates like Janice Cowden and Amy Beumer are "experts in living with cancer." This professionalization of advocacy marks a departure from historical models where patients were viewed primarily as subjects of study. METAvivor’s official stance is that by integrating the patient voice into trial design, researchers can identify more relevant endpoints, improve patient recruitment and retention, and ultimately accelerate the delivery of life-saving treatments.
Furthermore, the international response to METAvivor’s support models suggests a growing global recognition of the need for specialized MBC advocacy. The interest from Moroccan oncologists in the Peer-to-Peer training program indicates that the METAvivor model—combining rigorous scientific funding with robust emotional support—is a scalable framework that can be adapted to different cultural and healthcare contexts.
Implications: Looking Toward 2024 and Beyond
The activities of the past two months carry significant implications for the future of metastatic breast cancer treatment.
The Funding Gap and Research Momentum
The fact that 100% of METAvivor’s grant funding is dependent on donor contributions remains a central challenge. While the organization saw a high volume of LOIs this year, the ability to fund all 62 high-quality applications depends entirely on the success of ongoing fundraising efforts. The implication is clear: without continued public and corporate support, promising translational research may stall.
Diversity and Inclusion in Outreach
The launch of the R.I.S.E. program represents a strategic pivot toward health equity. By focusing on under-resourced populations, METAvivor is addressing a known disparity in oncology where minority and low-income patients often have less access to clinical trials and support networks. The success of R.I.S.E. could serve as a blueprint for other disease-specific non-profits aiming to improve equity in care.
The Scientific Trajectory
With 36 translational research applications in the pipeline, the upcoming year is poised to see significant advancements in how MBC is treated in the clinic. Translational research is often the "valley of death" for new drugs; METAvivor’s focus on this area ensures that scientific discoveries do not languish in laboratories but are moved forward into the human trials that Dr. Slamon and others are working to optimize.
Global Advocacy Leadership
As METAvivor exports its peer-to-peer training to countries like Morocco, it establishes itself not just as a domestic funder but as a global leader in MBC advocacy. This international expansion may lead to more diverse clinical trial populations and a more unified global front against metastatic disease.
In conclusion, METAvivor’s year-end activities represent a sophisticated blend of scientific stewardship and grassroots advocacy. From the halls of the San Antonio Breast Cancer Symposium to the boardrooms where grant decisions are made, the organization continues to champion the philosophy that for those living with Stage IV breast cancer, research is the only path to a cure. As the first week of January approaches, the community waits with anticipation for the announcement of the grants that will define the next chapter of MBC innovation.
About the Author
